Related Experiment Video

Updated: Jun 26, 2026

A Semi-Quantitative Drug Affinity Responsive Target Stability (DARTS) assay for studying Rapamycin/mTOR interaction
05:28

A Semi-Quantitative Drug Affinity Responsive Target Stability (DARTS) assay for studying Rapamycin/mTOR interaction

Published on: August 27, 2019

PTEN and rapamycin inhibiting the growth of K562 cells through regulating mTOR signaling pathway

Zhi Y Cheng1, Xiao L Guo, Xiao Y Yang

  • 1Department of Hematology and Heibei Institute of Hematology, The Second Hospital of Hebei Medical University, Shijiazhuang, PR China. dzczy@sohu.com

Journal of Experimental & Clinical Cancer Research : CR
|January 1, 2009
PubMed
Abstract

Insights

Tumor suppressor PTEN and rapamycin inhibit leukemia cell growth by regulating the mTOR pathway. Combining PTEN and low-dose rapamycin shows synergistic effects on inhibiting proliferation and promoting apoptosis in K562 cells.

Area of Science:

  • Molecular Biology
  • Cancer Research

Background:

  • The mammalian target of rapamycin (mTOR) signaling pathway is crucial in cell growth and proliferation.
  • Dysregulation of mTOR is implicated in various cancers, including leukemia.
  • PTEN is a known tumor suppressor that negatively regulates the PI3K/Akt/mTOR pathway.

Purpose of the Study:

  • To investigate the in vitro regulatory effects of the tumor suppressor PTEN on the mTOR signaling pathway.
  • To assess the impact of transfected PTEN and rapamycin on the growth inhibition and apoptosis induction of human leukemia K562 cells.

Main Methods:

  • K562 cells were transfected with an adenovirus vector carrying PTEN (Ad-PTEN-GFP).
  • Cells were treated with or without rapamycin, and proliferation and apoptosis were measured using MTT assay and flow cytometry.
  • mRNA and protein expression levels of key pathway components (PTEN, mTOR, cyclin D1, P27kip1, Akt, p-Akt) were analyzed using FQ-PCR and Western blotting.

Main Results:

  • PTEN gene transfection, with or without rapamycin, inhibited K562 cell proliferation.
  • Transfection with wild-type PTEN and rapamycin treatment upregulated PTEN and P27kip1 mRNA expression.
  • mTOR and cyclin D1 mRNA levels were downregulated in PTEN-transfected and rapamycin-treated K562 cells.

Conclusions:

  • PTEN and rapamycin act as upstream regulators, inhibiting mTOR expression.
  • Overexpressed PTEN combined with low-dose rapamycin may exhibit synergistic effects in inhibiting leukemia cell proliferation and promoting apoptosis.

More Related Videos

Development and Application of Rapamycin-regulated Tyrosine Phosphatases06:56

Development and Application of Rapamycin-regulated Tyrosine Phosphatases

Published on: September 6, 2024

Monitoring eIF4F Assembly by Measuring eIF4E-eIF4G Interaction in Live Cells08:47

Monitoring eIF4F Assembly by Measuring eIF4E-eIF4G Interaction in Live Cells

Published on: May 1, 2020

Related Concept Videos

PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...